Definition of Identical Drug Product and Formulation
- Identical drug products must have the same names and amounts of active medicinal ingredients per dosage unit.
- Must share identical excipients, components, and manufacturing processes as the principal product.
- Physical characteristics such as color, scoring, imprints, embossing, or debossing must be uniform across principal and identical products.
- Branded principal products cannot feature the brand name or markings identifiable with the brand on the tablet or capsule surface to avoid misbranding.
Clarifications on Compliance Requirements
- Compliance with the defined identical formulation criteria is mandatory for all principal and identical drug products.
- Applications for CLIDP submitted from November 30, 2014, onward must adhere strictly to these provisions.
- Non-compliant CLIDP applications will be denied outright and applicants advised to apply for full product registration (Certificate of Product Registration/CPR).
Requirements for Previously Approved Identical Drug Products
- Previously approved CLIDPs must apply for appropriate variations (e.g., change of capsule color) to achieve identity with the principal product.
- Variations must be filed prior to or during the renewal of authorizations.
- Principal products bearing brand names or identifiable markings on the dosage form must also submit variation applications.
Deadline and Consequences of Non-Compliance
- The deadline for filing variation applications is March 30, 2015.
- Failure to comply will result in disapproval of renewal applications for CLIDPs.
- Non-compliant products will be withdrawn from the market.
Legal and Administrative Authority
- Issued under the authority of the Food and Drug Administration (FDA), Department of Health.
- Signed by Assistant Secretary of Health and FDA OIC, reflecting official mandate and enforcement authority.
Key Legal Concepts
- Avoidance of duplication in regulatory review processes.
- Assurance of safety, efficacy, and quality by reliance on principal product evaluation.
- Strict definitions of drug product identity and uniformity to maintain regulatory consistency.
- Enforcement of compliance through denial of registration and market removal.
- Promotion of transparency and accountability among marketing authorization holders (MAHs).
This regulation clarifies and reinforces procedural and substantive requirements to ensure that identical drug products truly match their principal products in formulation and presentation, thereby facilitating regulatory efficiency and protecting public health.